Loading…
Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation
Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in t...
Saved in:
Published in: | Journal of molecular and cellular cardiology 2006-09, Vol.41 (3), p.488-495 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3 |
container_end_page | 495 |
container_issue | 3 |
container_start_page | 488 |
container_title | Journal of molecular and cellular cardiology |
container_volume | 41 |
creator | Chen, Frank C. Ogut, Ozgur Rhee, Albert Y. Hoit, Brian D. Brozovich, Frank V. |
description | Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ
+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ
+ MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ
+ MYPT1 expression. The change in LZ
+ MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ
+ MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation. |
doi_str_mv | 10.1016/j.yjmcc.2006.05.018 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68856125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022282806005839</els_id><sourcerecordid>68856125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</originalsourceid><addsrcrecordid>eNp9kE9v1DAQxS0EokvhEyAhn7gl-F-yzoEDWtFSqVU5wNny2pPGqyQOHu-i_fZ4uytx62lGmvdm5v0I-chZzRlvv-zq425yrhaMtTVrasb1K7LirGsq3Wj1mqwYE6ISWugr8g5xxxjrlJRvyRVvNW-UFCuCG7vkuKQw0iXBAeaMdDpGDDMdw9OQqRts6Zch4jLYbBFowNjHNFH8G7IbwvxEczyZEdIB6FxGdqTu9uFnNYEPNoOnB4vRh7H4c4jze_KmtyPCh0u9Jr9vvv_a_KjuH2_vNt_uK6eEzFV5EMTaSS3b1nMvhOXOCwWcudYqv_aN6KVXqmt7pzqunO0cg7UQbis0rLfymnw-711S_LMHzGYK6GAc7Qxxj6bVumm5aIpQnoUuRcQEvSlAJpuOhjNzYm125pm1ObE2rDGFdXF9uqzfb0vS_54L3CL4ehZACXkIkAy6ALMrVBK4bHwMLx74B3MHk-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68856125</pqid></control><display><type>article</type><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><source>ScienceDirect Journals</source><creator>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</creator><creatorcontrib>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</creatorcontrib><description>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ
+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ
+ MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ
+ MYPT1 expression. The change in LZ
+ MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ
+ MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</description><identifier>ISSN: 0022-2828</identifier><identifier>EISSN: 1095-8584</identifier><identifier>DOI: 10.1016/j.yjmcc.2006.05.018</identifier><identifier>PMID: 16815432</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>ACE inhibition ; Animals ; Antihypertensive Agents - pharmacology ; Captopril - pharmacology ; Congestive heart failure ; Cyclic GMP - metabolism ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Echocardiography - methods ; Flow mediated vasodilatation ; Heart Failure ; Male ; Myosin phosphatase ; Myosin-Light-Chain Phosphatase - chemistry ; Myosin-Light-Chain Phosphatase - metabolism ; Myosins - chemistry ; Nitric oxide ; Nitric Oxide - chemistry ; Protein Isoforms ; Rats ; Rats, Sprague-Dawley ; Vascular reactivity ; Vasodilatation ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of molecular and cellular cardiology, 2006-09, Vol.41 (3), p.488-495</ispartof><rights>2006 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</citedby><cites>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16815432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Frank C.</creatorcontrib><creatorcontrib>Ogut, Ozgur</creatorcontrib><creatorcontrib>Rhee, Albert Y.</creatorcontrib><creatorcontrib>Hoit, Brian D.</creatorcontrib><creatorcontrib>Brozovich, Frank V.</creatorcontrib><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><title>Journal of molecular and cellular cardiology</title><addtitle>J Mol Cell Cardiol</addtitle><description>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ
+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ
+ MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ
+ MYPT1 expression. The change in LZ
+ MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ
+ MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</description><subject>ACE inhibition</subject><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Captopril - pharmacology</subject><subject>Congestive heart failure</subject><subject>Cyclic GMP - metabolism</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Echocardiography - methods</subject><subject>Flow mediated vasodilatation</subject><subject>Heart Failure</subject><subject>Male</subject><subject>Myosin phosphatase</subject><subject>Myosin-Light-Chain Phosphatase - chemistry</subject><subject>Myosin-Light-Chain Phosphatase - metabolism</subject><subject>Myosins - chemistry</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - chemistry</subject><subject>Protein Isoforms</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Vascular reactivity</subject><subject>Vasodilatation</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0022-2828</issn><issn>1095-8584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE9v1DAQxS0EokvhEyAhn7gl-F-yzoEDWtFSqVU5wNny2pPGqyQOHu-i_fZ4uytx62lGmvdm5v0I-chZzRlvv-zq425yrhaMtTVrasb1K7LirGsq3Wj1mqwYE6ISWugr8g5xxxjrlJRvyRVvNW-UFCuCG7vkuKQw0iXBAeaMdDpGDDMdw9OQqRts6Zch4jLYbBFowNjHNFH8G7IbwvxEczyZEdIB6FxGdqTu9uFnNYEPNoOnB4vRh7H4c4jze_KmtyPCh0u9Jr9vvv_a_KjuH2_vNt_uK6eEzFV5EMTaSS3b1nMvhOXOCwWcudYqv_aN6KVXqmt7pzqunO0cg7UQbis0rLfymnw-711S_LMHzGYK6GAc7Qxxj6bVumm5aIpQnoUuRcQEvSlAJpuOhjNzYm125pm1ObE2rDGFdXF9uqzfb0vS_54L3CL4ehZACXkIkAy6ALMrVBK4bHwMLx74B3MHk-U</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>Chen, Frank C.</creator><creator>Ogut, Ozgur</creator><creator>Rhee, Albert Y.</creator><creator>Hoit, Brian D.</creator><creator>Brozovich, Frank V.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060901</creationdate><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><author>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>ACE inhibition</topic><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Captopril - pharmacology</topic><topic>Congestive heart failure</topic><topic>Cyclic GMP - metabolism</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Echocardiography - methods</topic><topic>Flow mediated vasodilatation</topic><topic>Heart Failure</topic><topic>Male</topic><topic>Myosin phosphatase</topic><topic>Myosin-Light-Chain Phosphatase - chemistry</topic><topic>Myosin-Light-Chain Phosphatase - metabolism</topic><topic>Myosins - chemistry</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - chemistry</topic><topic>Protein Isoforms</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Vascular reactivity</topic><topic>Vasodilatation</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Frank C.</creatorcontrib><creatorcontrib>Ogut, Ozgur</creatorcontrib><creatorcontrib>Rhee, Albert Y.</creatorcontrib><creatorcontrib>Hoit, Brian D.</creatorcontrib><creatorcontrib>Brozovich, Frank V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular and cellular cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Frank C.</au><au>Ogut, Ozgur</au><au>Rhee, Albert Y.</au><au>Hoit, Brian D.</au><au>Brozovich, Frank V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</atitle><jtitle>Journal of molecular and cellular cardiology</jtitle><addtitle>J Mol Cell Cardiol</addtitle><date>2006-09-01</date><risdate>2006</risdate><volume>41</volume><issue>3</issue><spage>488</spage><epage>495</epage><pages>488-495</pages><issn>0022-2828</issn><eissn>1095-8584</eissn><abstract>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ
+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ
+ MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ
+ MYPT1 expression. The change in LZ
+ MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ
+ MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>16815432</pmid><doi>10.1016/j.yjmcc.2006.05.018</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2828 |
ispartof | Journal of molecular and cellular cardiology, 2006-09, Vol.41 (3), p.488-495 |
issn | 0022-2828 1095-8584 |
language | eng |
recordid | cdi_proquest_miscellaneous_68856125 |
source | ScienceDirect Journals |
subjects | ACE inhibition Animals Antihypertensive Agents - pharmacology Captopril - pharmacology Congestive heart failure Cyclic GMP - metabolism Disease Models, Animal Dose-Response Relationship, Drug Echocardiography - methods Flow mediated vasodilatation Heart Failure Male Myosin phosphatase Myosin-Light-Chain Phosphatase - chemistry Myosin-Light-Chain Phosphatase - metabolism Myosins - chemistry Nitric oxide Nitric Oxide - chemistry Protein Isoforms Rats Rats, Sprague-Dawley Vascular reactivity Vasodilatation Vasodilator Agents - pharmacology |
title | Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Captopril%20prevents%20myosin%20light%20chain%20phosphatase%20isoform%20switching%20to%20preserve%20normal%20cGMP-mediated%20vasodilatation&rft.jtitle=Journal%20of%20molecular%20and%20cellular%20cardiology&rft.au=Chen,%20Frank%20C.&rft.date=2006-09-01&rft.volume=41&rft.issue=3&rft.spage=488&rft.epage=495&rft.pages=488-495&rft.issn=0022-2828&rft.eissn=1095-8584&rft_id=info:doi/10.1016/j.yjmcc.2006.05.018&rft_dat=%3Cproquest_cross%3E68856125%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68856125&rft_id=info:pmid/16815432&rfr_iscdi=true |